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Abstract
Background:  Advances made in the area of microarray comparative genomic hybridization
(aCGH) have enabled the interrogation of the entire genome at a previously unattainable
resolution. This has lead to the discovery of a novel class of alternative entities called large-scale
copy number variations (CNVs). These CNVs are often found in regions of closely linked sequence
homology called duplicons that are thought to facilitate genomic rearrangements in some classes
of neoplasia. Recently, it was proposed that duplicons located near the recurrent translocation
break points on chromosomes 9 and 22 in chronic myeloid leukemia (CML) may facilitate this
tumor-specific translocation. Furthermore, ~15–20% of CML patients also carry a microdeletion
on the derivative 9 chromosome (der(9)) and these patients have a poor prognosis. It has been
hypothesised that der(9) deletion patients have increased levels of chromosomal instability.
Results: In this study aCGH was performed and identified a CNV (RP11-125A5, hereafter called
CNV14q12) that was present as a genomic gain or loss in 10% of control DNA samples derived
from cytogenetically normal individuals. CNV14q12 was the same clone identified by Iafrate et al.
as a CNV. Real-time polymerase chain reaction (Q-PCR) was used to determine the relative
frequency of this CNV in DNA from a series of 16 CML patients (both with and without a der(9)
deletion) together with DNA derived from 36 paediatric solid tumors in comparison to the
incidence of CNV in control DNA. CNV14q12 was present in ~50% of both tumor and CML DNA,
but was found in 72% of CML bearing a der(9) microdeletion. Chi square analysis found a
statistically significant difference (p ≤ 0.001) between the incidence of this CNV in cancer and
normal DNA and a slightly increased incidence in CML with deletions in comparison to those CML
without a detectable deletion.
Conclusion:  The increased incidence of CNV14q12 in tumor samples suggests that either
acquired or inherited genomic variation of this new class of variation may be associated with onset
or progression of neoplasia.
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Background
Genes typically affect an individual's susceptibility to a
disease because mutations change either the amount or
the composition of the protein encoded by the gene. It has
recently been suggested that copy number variation may
contribute to susceptibility to common diseases [1].
Microarray comparative genomic hybridization (aCGH)
is a powerful tool that allows for high-resolution interro-
gation of genomic copy number imbalances of unique
genomic sequences throughout the entire genome in a
single experiment [2]. The repetitive fraction of the
genome comprises diverse classes of repetitive DNA that is
often polymorphic. Of these, the most recently discovered
repeat-rich regions are those containing a high number of
large-scale copy number variations (CNVs) [3] that
involve the loss or gain of large fragments of DNA exceed-
ing hundreds of kilobases. CNVs are present in the general
population at varying degrees, and their role in cancer is
poorly defined at the present time. While the mechanism
responsible for generating the variation is unknown,
CNVs have been shown to be preferentially located near
known segmental duplications, or duplicons [4]. Dupli-
cons are large regions of the genome (> 1 kb) that exhibit
high sequence homology (90–98% sequence identity)
[5], and have been linked to recurrent gene amplification
in tumors [6].
Chronic myeloid leukemia (CML) is characterised cytoge-
netically by the Philadelphia translocation (t(9;22)),
which results in the formation of a smaller than normal
chromosome 22 known as the Philadelphia chromo-
some, and the derivative chromosome 9 (der(9)) [7].
While a great deal is known about the effects of the Phila-
delphia translocation, there is limited knowledge of the
recombinational mechanisms that lead to genomic rear-
rangement. Saglio et al. first noted significant sequence
homologies in the translocated regions and identified a
76 kb duplicon located near the Abl1 and Bcr genes on
chromosomes 9 and 22 respectively. This duplicon may
facilitate the Philadelphia translocation in CML by favour-
ing homologous exchange between non-syntenic regions,
or through double stranded breaks [8]. These exchanges
suggest an error within a DNA repair mechanism respon-
sible for maintaining genome integrity. Similarly, it has
been suggested that defects of recombinational/repair
pathways may facilitate acquisition of additional cytoge-
netic abnormalities in CML [9,10].
This study was initiated to investigate whether CNVs were
associated with acquisition of more complex genomic
alterations in CML. In particular, we were interested in
determining if a CNV-dependent mechanism was associ-
ated with the presence of microdeletions seen on the
der(9) in 15–20% of patients carrying a microdeletion
[11,12]. The potential of CML patients with microdele-
tions of der(9) to be more generally associated with either
acquired or inherited differences in CNVs has not been
analyzed by aCGH methods. aCGH methods are begin-
ning to document both the number of CNVs and their
locations in phenotypically normal individuals [3,4]. It is
not yet clear what role CNVs play in CML and cancer in
general, however, it has been suggested that these
sequences may be intrinsically unstable and may thus be
hotspots for genomic alterations [3]. This study reports
the identification of CNV14q12, a highly imbalanced
region found to be present at a higher frequency in neo-
plastic samples in comparison to control DNA.
Results
Microarray comparative genomic hybridization (aCGH) 
analysis
aCGH was performed on 5 chronic myeloid leukemia
(CML) patients with a known deletion on the derivative 9
chromosome (der(9)). The presence of a deletion in these
patients was assessed by real-time polymerase chain reac-
tion (Q-PCR) and/or fluorescence in situ hybridization
(FISH) [13]. aCGH was performed using commercially
available 1–2 MB resolution Spectral Chip 2600 BAC
arrays (Spectral Genomics, Houston TX, USA) and ana-
lyzed using Normalise Suite v2.5 [14]. An unexpected find-
ing was the presence of a gain on chromosome 14 located
at the BAC clone RP11-125A5, hereafter called
CNV14q12, found in 3 of the 5 patient samples. The same
clone showed a deletion in 1 CML sample (figure 1). The
BAC clones on the array nearest to RP11-125A5 both
upstream and downstream are RP11-529E4 and RP11-
329K12, respectively, both of which showed normal copy
Microarray comparative genomic hybridization results for 5  chronic myeloid leukemia patients for chromosome 14 Figure 1
Microarray comparative genomic hybridization results for 5 
chronic myeloid leukemia patients for chromosome 14. 
Arrow indicates CNV14q12. A) Arrow denotes 1 sample 
with a CNV14q12 deletion. B) Arrow denotes 1 sample with 
no change in the copy number of CNV14q12. C) Arrows 
show 3 samples with a copy number increase in the 
CNV14q12 region.BMC Genomics 2006, 7:138 http://www.biomedcentral.com/1471-2164/7/138
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numbers in all experiments, thereby defining the minimal
region of gain to a 1.2 MB region centered at RP11-125A5.
aCGH analysis using a sub-megabase tiling path array
(SMRT-array, BC Cancer Agency, Vancouver, Canada)[2],
was performed on 2 samples with a deletion on the der(9)
chromosome, as well as one sample not showing the
der(9) deletion, all of which carry the CNV14q12 event (2
show a gain, and one a deletion). The gain or loss of
genomic material at CNV14q12 does not correlate with
the presence of a deletion on the der(9). Der(9) deletion
status was determined by FISH analysis and confirmed by
Q-PCR. Unfortunately, the normal control DNA used in
these experiments was different from that used for both
the 1–2 MB resolution microarrays, and the Q-PCR anal-
ysis, and it appears that this DNA carried the CNV14q12.
As such, no other varitation was seen in any of the cases.
The SMTR-array was able to identify the deletion on chro-
mosomes 9 and 22 in one of the 2 cases where a deletion
had been previously identified by FISH and Q-PCR analy-
sis (figure 2). Project files for the Spectral Genomics and
SMRT array dataset can be viewed [see Additional File 1]
and [Additional File 2] respectively.
Q-PCR results and statistical analysis
Relative quantification of the amount of genomic mate-
rial at CNV14q12 was determined using Q-PCR, where
the relative quantity is normalized to a haploid value.
Based on all of the cytogenetically normal samples
(excluding the single sample that showed a marked copy
number gain) the mean haploid value was 1.02 with a
standard deviation (SD) of 0.13. A 2 SD threshold was
used to assign a normal copy range of 0.76 – 1.28. Based
on Q-PCR analysis of 3 CML patient samples that had
been shown to have a gain by aCGH analysis, the mini-
mum value for a gain (mean – 2SD) was defined as 1.43
(1.99 ± 0.28). A deletion of CNV14q12 was found in one
CML patient by aCGH analysis. The mean Q-PCR value
for this sample was 0.45, establishing a range of 0.31–
0.65 for a deletion. The results of the Q-PCR reactions
based on the ranges defined here are summarized in table
1 (also see figure 3).
The chi-square test (χ2) was used to compare the copy
number of the CNV14q12 variation (gains and losses)
between each sample group. Based on χ2 analysis, there
was a statistically significant difference in the number of
changes in cancer patients with additional cytogenetic
abnormalities (both CML cohorts plus the paediatric solid
tumor cohort) versus cytogenetically normal individuals
(p ≤ 0.01). Individual analysis of CML patients with a
deletion (p ≤ 0.001), CML without a der(9) deletion (p ≤
0.01), and paediatric solid tumor samples (p ≤ 0.001)
revealed a statistically significant difference between the
number of variants in CNV14q12 when compared to
cytogenetically normal individuals. Comparison of the
number of variants in CNV14q12 seen in CML patients
with and without a der(9) deletion showed a slight trend
but no statistical difference in the frequency of the
CNV14q12 variation in the presence of a der(9) deletion
(p ≤ 1). However, the sample size of the CML patients
with a deletion was small (n = 7) and thus statistical anal-
ysis was inappropriate. A larger patient cohort will be
required to determine whether there is a statistical associ-
ation present. Comparison of the CML cohorts, with or
without a der(9) deletion, to the paediatric solid tumor
cohort did not reveal a statistically significant difference
(p ≤ 0.2 for both). As in the case of CML, a larger cohort
of patients with a der(9) deletion may yet reveal a differ-
SMRT-array results showing the deletion on chromosomes 9  and 22 that are the result of the derivative 9 chromosome  (der(9)) deletion in a chronic myeloid leukemia (CML)  patient Figure 2
SMRT-array results showing the deletion on chromosomes 9 
and 22 that are the result of the derivative 9 chromosome 
(der(9)) deletion in a chronic myeloid leukemia (CML) 
patient. The dotted red line denotes the 2 standard deviation 
cut-off to identify a deletion while the green dashed line 
marks the 2 standard deviation cut-off for a gain. A) Chro-
mosome 9 alterations identified using the SMRT-array. The 
red arrow shows the deletion extending from 9q33.3 to 
9q34.1. B) Chromosome 22. The deletion of chromosome 
22 material, located around 22q11.2, on the der(9) chromo-
some is shown by the red arrow. C) Chromosome 14 from 
the same CML sample with the der(9) deletion, and shown to 
have the CNV14q12 event using another microarray com-
parative genomic hybridization platform as well as real-time 
polymerase chain reaction. The black arrow marks the site of 
CNV14q12 and, due to the use of a different normal genomic 
DNA sample, does not display the expected gain of genomic 
material. The most distal copy number variation was seen 
only in this sample and therefore not studied further.BMC Genomics 2006, 7:138 http://www.biomedcentral.com/1471-2164/7/138
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ence in the frequency of this variation as compared to pae-
diatric solid tumors.
Location of duplicated material using dual colour FISH
Dual colour FISH (D-FISH) was used to determine the
location of the gained genomic DNA. The results (figure
4) identified a cytogenetic duplication of genetic material
on a single chromosome in an adjacent position. Quanti-
fication-FISH (Q-FISH), a technique that utilizes the rela-
tive signal intensity of a target signal compared to a
control probe [15], showed that there is a gain of
CNV14q12 material [see Additional file 3].
In silico analysis of the CNV14q12 genomic region
In silico analysis of the CNV14q12 genomic locus located
on chromosome 14 in the q12 cytoband revealed the
presence of 5 well characterised genes. Three of these
genes are pseudogenes – BCL2/adenovirus E1B 19 kDa
interacting protein (BNIP3P), ribosomal protein L26
pseudogene 3 (RPL26P3), and basic transcription factor 3
pseudogene 2 (BTF3P2) – while one is a hypothetical gene
(LOC387978). The remaining gene is FOXG1B (forkhead
box G1B; also called BF1  (brain factor 1), forkhead
homolog-like 1 (FKHL1), QIN (QIN oncogene)). The role
of  FOXG1B  has been extensively studied in neuronal
development due to its expression in the human telen-
cephalon. This gene is also expressed in the stomach, kid-
ney, aorta, ovary and testis, and the cochlea. It is uncertain
whether it is expressed in the bone marrow and whether
FOXG1B would play a role in mediating survival in CML.
The genomic architecture of the CNV14q12 region
includes 2 segmental duplications located upstream of
RP11-529E4. Neither segmental duplication, nor any oth-
ers, spans the amplified region in such a way that dupli-
cons could facilitate the alterations observed here. L1-
interspersed nuclear elements (LINEs) are found through-
out the region which is not uncommon. Interestingly, 2
large LINE repeats (~6 kb and ~5.5 kb) are present at the
5' end of RP11-125A5. In addition, there are a large
number of short interspersed nuclear elements that, like
LINEs, are distributed throughout the genome.
Fluorescence in situ hybridization (FISH) image of CNV14q12  (red) and RP11-79B13 (green), a control region on chromo- some 14 that did not show a deviation from normal copy  number according to the microarray comparative genomic  hybridization experiments Figure 4
Fluorescence in situ hybridization (FISH) image of CNV14q12 
(red) and RP11-79B13 (green), a control region on chromo-
some 14 that did not show a deviation from normal copy 
number according to the microarray comparative genomic 
hybridization experiments. The arrow marks the pair of FISH 
signals at CNV14q12. Quantitative-FISH showed that the 
marked probe was indeed due to hybridization at 2 adjacent 
loci rather than a split signal.
A graphical representation of real-time polymerase chain  reaction results Figure 3
A graphical representation of real-time polymerase chain 
reaction results.
Table 1: Real-time polymerase chain reaction results. 
Occurrence of a copy number variation at 14q12
Cohort Change No Change Total χ2 p-
value
Normal 2 23 25
CML* with der(9)+ deletion 5 2 7 ≤ 0.001
CML no der(9) deletion 8 9 17 ≤ 0.01
All CML 13 11 24 ≤ 0.001
Paediatric Solid Tumor 21 22 43 ≤ 0.001
All Tumors 34 33 67 ≤ 0.001
*Chronic myeloid leukemia
+derivative 9 chromosomeBMC Genomics 2006, 7:138 http://www.biomedcentral.com/1471-2164/7/138
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Discussion
Large-scale copy number variations (CNVs), and dupli-
cons in general, are difficult to integrate into the human
genome [5] and the high sequence homology has recently
been shown to affect microarray comparative genomic
hybridization (aCGH) results [16]. A study by Locke et al.
showed that the presence of duplicon material in BACs
spotted on a 15q11-q13 region specific array resulted in
muted detection of genomic alterations. They also sug-
gested that the presence of duplicons is a consideration
when designing and analyzing microarrays for aCGH
[16].
In a recent report on the presence of CNVs located in the
genome of normal individuals, Iafrate et al. noted that
25% of the CNVs identified mapped to regions overlap-
ping previously identified segmental duplications [4].
They showed that the correlation with known duplicons
was significantly different from that determined for all
clones on the array (p < 0.0001) [4]. Another report by
Sebat et al. confirmed that CNVs were more prevalently
located at known duplicon sites than would be expected if
randomly distributed. Sebat et al. suggest that duplicons,
unstable regions, and CNVs are probably the result of a
common underlying mechanism [3].
The results presented in this study also suggest an
increased incidence of the CNV14q12 imbalance in neo-
plasias such as chronic myeloid leukemia (CML) and
solid tumors of childhood. Interestingly, in a study of 55
individuals, Iafrate et al. found similar results for
CNV14q12 when examining cytogenetic aberrations in
normal blood lymphocytes. [4] They performed aCGH
analysis of 36 cytogenetically normal individuals as well
as 16 individuals with a known constitutional cytogenetic
abnormality. The results of this study identified a number
of CNVs including 6 clones that were abnormal at a fre-
quency of >20%. Among these clones was CNV14q12
(RP11-125A5). A chi-square comparison of the preva-
lence of individuals with and without additional cytoge-
netic abnormalities revealed a statistically significant
increase in the likelihood of having a variation at this
locus in the presence of additional cytogenetic abnormal-
ities (p ≤ 0.001). This suggests that the mechanism under-
lying the formation of this CNV and the genomic
abnormalities may be the same. However, because nor-
mal constitutional DNA was not available from any por-
trait within this study group, it was not possible to
determine whether neoplastic cells acquired CNV as part
of oncogenetic progression.
Fluorescence in situ hybridization (FISH) analysis of CML
patient material revealed that CNV14q12 material was
gained on a single chromosome located directly adjacent
to the homologous material (figure 4). Since a split FISH
signal would display the same pattern, quantification of
the signal intensity over a minimum of 30 metaphases
was performed on this CML patient sample as well as a
series of cytogenetically normal individuals [see Addi-
tional file 3]. The results of this analysis revealed an
increase in the CNV14q12 material thereby confirming
the aCGH and the real-time polymerase chain reaction
(Q-PCR) data. This duplication, along with the Q-PCR
results that indicate both a gain and a loss to be present at
this locus in the series of patients studied, suggests that
duplication/deletion occur through incorrect homolo-
gous recombination between repeats flanking this
genomic locus.
In silico analysis of the region surrounding RP11-125A5
failed to reveal any duplicons which would be a likely
mechanism for mediating the CNV14q12 events, how-
ever, current genomic architecture of the CNV14q12
region is derived from sequence data obtained from a
small number of individuals and it is possible that the fre-
quency and diversity of CNV variation at 14q12 in
humans may be much more extensive than is apparent by
analysis using current NCBI datasets.
Analysis of L1-interspersed nuclear elements (LINEs) ele-
ments in the region did identify 2 large L1 elements of the
PA7 subfamily. These elements are ~6 kb and ~5.5 kb
respectively, and could possibly mediate unequal homol-
ogous recombination resulting in deletion or gain of a
copy of this genomic region. LINE elements have been
shown to play a role in disease formation through dele-
tions of small (~5 kb) fragments of DNA [17]. A number
of diseases have now been shown to be the result of rear-
rangements between repeat regions [17,18]. In general,
the greater the distance between the repeats, the larger the
repeats need to be in order to mediate the event [17]. A
recent report has shown that LINEs [18] and palindromic
AT-rich repeats are associated with acquired chromosome
translocation frequencies that can mediate phenotypes
generated by the duplication of a large fragment (~450
kb) of DNA [19].
Conclusion
The results presented here identified a copy number vari-
ation, CNV14q12, which was observed at a high level in
neoplastic DNA samples. The limitations of the sample
size precluded a detailed statistical analysis of subsets
within the study group. Despite being present at a high
level in both chronic myeloid leukemia (CML) cohorts,
the presence of CNV14q12 failed to show a strong signif-
icant association with the presence of the derivative chro-
mosome 9 (der(9)) deletion. Likewise, the occurrence of
the CNV14q12 variation was more prevalent in the paedi-
atric tumor cohort than in control DNA. These data sug-
gest that the occurrence of CNV14q12 may be indicativeBMC Genomics 2006, 7:138 http://www.biomedcentral.com/1471-2164/7/138
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of an error in a pathway responsible for maintaining DNA
integrity in neoplasia. A comparison of the cytogenetic
profile of patients with CNV14q12 in a familial cohort
would indicate whether this is an acquired event second-
ary to the primary cytogenetic abnormality, or a primary
event indicative of faulty DNA replication pathways.
Methods
Samples
Cytogenetically normal samples
A series of 19 anonymous, ethnically diverse, cytogeneti-
cally normal samples were used for real-time polymerase
chain reaction (Q-PCR) analysis. The samples were
acquired according to the institutional guidelines of the
research ethics board of the University Health Network
Research Ethics Board (Toronto, Canada). Cytogenetic
analysis of these samples failed to identify any abnormal-
ities. All samples were derived from an unaffected parent
as part of routine cytogenetic screening. Of these 19 con-
trol samples, 4 were of northern European origin, 3 from
southern Europe, 1 Caucasian, 3 Jewish, 2 Native Indian,
2 Filipino, 2 Black, and 2 West Indian. In addition, one
commercially available normal female genomic DNA
sample was purchased from Promega (Napeen, Canada).
Chronic myeloid leukemia (CML) patient samples
Two groups of CML samples (derived from routine Uni-
versity Health Network laboratory diagnostic procedures
according to the institutional guidelines of the research
ethics board) were studied. The first group consisted of
CML patients who, by Q-PCR and/or fluorescence in situ
hybridization (FISH) analysis, were determined to carry a
deletion on the derivative chromosome 9 (der(9)) at the
site of the Philadelphia translocation breakpoint [13].
This group consisted of 7 patient samples. The second
group, consisting of 17 patient samples, was identified as
not having a deletion on the der(9) chromosome by Q-
PCR analysis [13]. The two groups did not differ signifi-
cantly in terms of age, percentage of blasts, or percentage
of basophils. There was a difference in the ratio of males
to females between the two groups, however this differ-
ence can be attributed to the small sample size of the
der(9) deletion patients.
Paediatric solid tumor control cohort
Thirty-six tumor DNA samples derived from a broad selec-
tion of paediatric patients (12 medulloblastomas, 12 neu-
roblastomas, 7 Ewing's sarcomas, 5 Rhabdosarcomas)
who were naïve to therapy were acquired according to the
institutional guidelines of the research ethics board of the
Hospital for Sick Children Research Ethics Board
(Toronto, Canada). The samples were used as a control to
determine the prevalence of an abnormal event at
CNV14q12 in cancer samples.
Reference sample for Q-PCR analysis
The reference sample selected for these experiments was
genomic male DNA purchased from Promega (Napeen,
Canada). In addition, a genomic female DNA (Promega,
Napeen, Canada) was also used for the Q-PCR analysis,
after determining, based on Q-PCR analysis, that the rela-
tive copy numbers of both the male and female reference
DNA were the same (p = 0.6572).
Microarray comparative genomic hybridization (aCGH) and 
microarray analysis
Genomic DNA was obtained from all tumor samples [see
Additional file 4] using standard phenol chloroform
extraction methods. The normal human reference DNA
comprised of an equimolar mixture of DNA derived from
multiple male donors (Promega, Madison, WI). The
genomic array slides were obtained from Spectral Genom-
ics (Houston, TX) and comprised of 2632 large insert
clones (BACs/PACs) spaced ~1–2 Mb apart. The protocol
used was as suggested by the suppliers. In brief, 2 μg each
of genomic tumor and normal DNA were directly labelled
with Cy3- or Cy5-dCTP (Amersham, Baie D'Urfe, Canada)
using random priming. Following hybridization the
microarrays were washed using 50% formamide/2 × SSC
(20 minutes), 0.1% Ipegal/2 × SSC (20 minutes), and 0.2
× SSC (10 minutes) all pre-warmed to 50°C. A final wash
with de-ionized distilled water was carried out. Air-dried
microarray slides were scanned with an Axon GenePix
4000A confocal scanner, and fluorescence intensities
quantified with the GenePix Pro 3.0 software (Axon
Instruments, Union City, CA). Hybridizations were car-
ried out in duplicate with fluor reversals to ensure that
labelling differences did not affect imbalance assign-
ments. Details concerning software, normalization, and
imbalance assignments have been described previously
[20] and are available at [21]. Using this software, a slid-
ing window (n = 80 features) was used to remove some of
the background noise present in the array, and a 2 stand-
ard deviation threshold was chosen for the assignment of
imbalance.
Submegabase tiling path array (SMRT; BC Cancer Agency,
Vancouver, Canada) used consisted of 32,433 bacterial
artificial chromosomal DNA arranged in a tiling path
spanning the entire genome. Hybridization was carried
out as described by Ishkanian et al on 2 samples with a
deletion of the der(9) chromosome, as well as one sample
not showing the der(9) deletion, all of which carry the
CNV14q12 variant. Normal human control DNA was
derived from a pool of 6 normal individuals (Promega,
Madison, WI), unfortunately this sample carried the
CNV14q12 and as such no variation could be seen. This
normal reference DNA was different from that used in the
aCGH and Q-PCR analysis done on the Spectral Genom-
ics Platform.BMC Genomics 2006, 7:138 http://www.biomedcentral.com/1471-2164/7/138
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The data discussed in this publication have been depos-
ited in NCBIs Gene Expression Omnibus (GEO) [22] and
are accessible through GEO Series accession number
GSE4860 [23].
Quantitative-fluorescence in situ hybridization (Q-FISH)
The probes used were selected using the Map Viewer pro-
gram available from NCBI []. The BAC clones correspond-
ing to regions of interest were obtained from BACPAC
Resources Center operated by the Children's Hospital
Oakland Research Institute []. The BAC clones selected
were RP11-125A5 and RP11-79B13, both of which are
located on chromosome 14. Clone RP11-79B13 was used
as the control.
One microgram of the BAC clone was labelled overnight
at 15°C using a Nick Translation kit (Vysis, Downers
Grove IL, USA) with either spectrum green or spectrum
orange. For each slide, 10 μl of probe was used. Each
probe was initially verified by FISH mapping onto met-
aphase spreads generated from lymphocytes from a nor-
mal, healthy individual.
Image acquisition was performed using a Zeiss Axioskop
2 Plus microscope (Jena, Germany) equipped with the
appropriate filter sets. As a normal control was performed
with each experiment, the exposure time may have varied
between experiments due to changes in the signal inten-
sity; however, within each experiment the exposure time
for each fluorochrome was identical so that quantification
of the signal was applicable.
Analysis of the signal intensities was performed using
ImageJ []. Q-FISH relies on a relative quantification of a
signal of interest with respect to the intensity of the signal
for a control region. A minimum of 30 individual nuclei
were analyzed and the average ratio of the signal of inter-
est to the control signal was compared to the ratio deter-
mined for the normal sample run in the same experiment.
To confirm that the selected control clone was a suitable
control for the analysis, a histogram of the control spot
across the captured images was generated for each sample
and compared to the histogram of the control signal in the
normal sample. This comparison revealed highly similar
single mode distribution of the control signal, thereby
indicating that the control clone was suitable for the anal-
ysis (data not shown).
Q-PCR
The sequences used to design the primers to validate
imbalance at CNV14q12 were obtained from end
sequencing of the BAC clones RP11-125A5 (AQ345961)
and RP11-79B13 (AQ284031). The selection of these
clones was based on the analysis of the 5 Spectral Chip
2600 microarrays performed. aCGH analysis identified
RP11-125A5 to be gained in 3 of the 5 cases and lost in 1
case, based on a threshold of 2 standard deviations (SD).
Indeed the gain seen in CNV14q12 in all three cases was
significant at up to 8 SD as was the loss. RP11-79B13 was
selected as the control clone, as in none of the microarrays
was this region altered, with the deviation from baseline
at this clone being negligible (normalized values of
0.988–1.007, SD = 0.009, for all 5 arrays). The control
region selected was also on chromosome 14 in order to
negate the impact of ploidy change of this chromosome
on the Q-PCR analysis.
Primers for the study (table 2) were designed using
primer3 []. BLAST analysis [] showed the sequences to be
specific for the region of interest. Q-PCR reactions were
carried out as previously described [13]. Briefly, each reac-
tion included the optimal primer concentration (table 2),
20 ng DNA, 10 μl of 2X SYBR Green master mix (Applied
Biosystems, Foster City, CA), in a volume of 20 μl. Cycling
conditions began with 5 minutes at 50°C followed by 10
minutes at 95°C. This was followed by 40 cycles of: 15
seconds at 95°C, 1 minute at 60°C. Q-PCR was carried
out on an ABI Prism 7900HT instrument with a 384-well
block (Applied Biosystems, Foster City, CA). All reactions
were performed in triplicate. A sample was considered to
have a failed reaction and need repeating in the event that
more than one of the triplicates failed. Relative quantifica-
tion using the ΔΔCT method with a threshold of 0.2 was
used for the analysis of the Q-PCR results.
Table 2: Primer information. Primers used to assess the CNV14q12 and RP11-79B13 genomic regions.
Primer Accession Sequence Size Conc.
125A5_F AQ345961 AGCATGTCCCTCTCTCAACC 118 bp 50 nM
125A5_R AQ345961 GCAGCCTATAACCCCCTTTT
79B13_F AQ284031 CAGGATGTCCACAGCCATAA 140 bp 100 nM
79B13_R AQ284031 TCTGTTGGGTCCTGAGGAAGBMC Genomics 2006, 7:138 http://www.biomedcentral.com/1471-2164/7/138
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